MDT Stock Recent News

Medtronic (MDT 2.62%) stock was a fairly hot item as the trading week kicked off, with investors pushing the shares up by almost 3% in value. They liked the medical device specialist's latest piece of news about one of its products, and reacted accordingly.

Dividend Aristocrats are outperforming the S&P 500 in 2025, demonstrating resilience, with NOBL up 1.78% YTD versus SPY's 4.9% decline. Top performers include Consolidated Edison (+22.98%), Brown & Brown (+20.65%), and AbbVie (+16.61%), showcasing strong double-digit gains. 29 out of 69 Dividend Aristocrats have announced dividend increases in 2025, with an average growth rate of 4.15%.

Healthcare can be a complex sector, and it is one that I long ago decided to outsource to the industry professionals who run closed-end fund Blackrock Health Sciences Trust. But I couldn't resist dipping my toe into the sector when I saw the historically high yield on offer from Medtronic (MDT 0.88%), one of the largest and most diversified medical device makers.

Medtronic (MDT) concluded the recent trading session at $88.98, signifying a +0.85% move from its prior day's close.

Fears of a looming recession seem to be rising, partly fueled by President Donald Trump's macroeconomic policies. While it's impossible to predict whether an economic downturn is indeed coming, it's not a bad idea for investors to purchase shares of companies that are likely to perform relatively well in case it does happen.

Boston Scientific, Abbott and Medtronic are included in this Analyst Blog.

Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.

Medtronic (MDT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Upgraded Medtronic to a ‘Buy' rating with a fair value of $105 per share, driven by strong growth in Cardiac Ablation Solutions and TAVR markets. Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth, highlighting significant momentum in its Cardiac Ablation Solutions business. The company's structural heart business, especially the Evolut FX+ TAVR system, is showing strong adoption and competitive advantages over Edwards Lifesciences's SAPIEN TAVR product.

The U.S. Food and Drug Administration on Tuesday classified the recall of Medtronic's embolization device as "most serious", following reports of the deaths of four patients.